Skip to content

Main Navigation

  • About us
    • History
    • Mission, vision & values
    • Leadership
    • Scientific advisors
    • Our team
    • Social impact (CSR)
  • Science & Services
    • Contexts of use
      • Trial design and analyses
      • Program strategies and efficiencies
      • Special/specific populations
      • Special considerations
      • Regulatory interactions
    • Pharmetheus Platforms
      • Model-Informed Drug Development
      • PBPK & PBBM
      • Pharmacometrics
      • QSP
    • Solutions
      • Milestone Analysis
      • Embedded Scientist
      • Expert Advice
      • Training workshop
      • Scientific Publication
    • Specific services
      • Model-Informed Bioequivalence & Biosimilarity
      • Accelerated submission
      • Concentration-QTc (C-QTc) modeling
      • Data-driven strategies for pediatric success
    • Publications
    • Case studies
  • Careers
    • Working with us
    • Open positions
    • Employee stories
  • Events
  • News
  • Contact us
  • LinkedIn

Development of efficient CAR-T cell clinical study designs: Towards understanding of novel anticancer therapies through optimal experimental design

PAGE 33 (2025) Abstr 11783
Klima F, Mc Laughlin AM, Michelet R, Winkler A, Huisinga W, Haussmann K, Künkele A, Hooker AC, Kloft C.
ConferenceMethodologyOncologyPharmacometricsTrial design and analysis

Pharmetheus Affiliates

Portrait-of-Anna-Mc-Laughlin_Pharmetheus
Senior Director, MIDD Consultant

Anna Mc Laughlin

See bio
Portrait-of-Andrew-Hooker_Pharmetheus
Scientific Advisor

Andrew Hooker

See bio

Contact

Pharmetheus AB
Kungsängstull 4
753 19 Uppsala, Sweden

Visiting address: Dragarbrunnsgatan 77, 5th floor

Contact us

Links

  • Home
  • Newsletter
  • LinkedIn
  • Whistleblower
  • Privacy Policy
  • Cookie Policy
  • Consent Preferences

Services

  • Contexts of use
  • Pharmetheus platforms
  • Solutions
  • Case studies
  • Publications

About

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.